These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 16891463

  • 41. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L.
    Oncotarget; 2015 Dec 29; 6(42):44563-78. PubMed ID: 26575424
    [Abstract] [Full Text] [Related]

  • 42. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.
    Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y, Jiang H, Luo C, Lin L, Ding J.
    J Cell Mol Med; 2012 Oct 29; 16(10):2321-30. PubMed ID: 22304225
    [Abstract] [Full Text] [Related]

  • 43. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec 29; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

  • 44. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
    Azad AK, Zhabyeyev P, Vanhaesebroeck B, Eitzen G, Oudit GY, Moore RB, Murray AG.
    Oncogene; 2020 Oct 29; 39(41):6480-6492. PubMed ID: 32879446
    [Abstract] [Full Text] [Related]

  • 45. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC.
    Curr Cancer Drug Targets; 2009 Sep 29; 9(6):738-47. PubMed ID: 19754358
    [Abstract] [Full Text] [Related]

  • 46. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.
    Clin Cancer Res; 2008 Nov 15; 14(22):7272-83. PubMed ID: 19010843
    [Abstract] [Full Text] [Related]

  • 47. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, Serra SC, D'Incalci M, Cavalletti E, Giavazzi R, Damia G, Camboni G.
    Cancer Res; 2011 Feb 15; 71(4):1396-405. PubMed ID: 21212416
    [Abstract] [Full Text] [Related]

  • 48. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM, Gebhard DF, Andresen CJ.
    Eur J Gastroenterol Hepatol; 2012 May 15; 24(5):563-74. PubMed ID: 22314934
    [Abstract] [Full Text] [Related]

  • 49. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.
    Siekmann IK, Dierck K, Prall S, Klokow M, Strauss J, Buhs S, Wrzeszcz A, Bockmayr M, Beck F, Trochimiuk M, Gottschling K, Martens V, Khosh-Naucke M, Gerull H, Müller J, Behrmann L, Blohm M, Zahedi RP, Jeremias I, Sickmann A, Nollau P, Horstmann MA.
    Blood Adv; 2018 Oct 09; 2(19):2554-2567. PubMed ID: 30301811
    [Abstract] [Full Text] [Related]

  • 50. Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential.
    Devambatla RKV, Choudhary S, Ihnat M, Hamel E, Mooberry SL, Gangjee A.
    Bioorg Med Chem Lett; 2018 Oct 01; 28(18):3085-3093. PubMed ID: 30098869
    [Abstract] [Full Text] [Related]

  • 51. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q, Li Q, Fan H.
    Arch Dermatol Res; 2024 Jul 03; 316(7):447. PubMed ID: 38958761
    [Abstract] [Full Text] [Related]

  • 52. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.
    Mol Cancer Ther; 2012 Mar 03; 11(3):670-9. PubMed ID: 22203728
    [Abstract] [Full Text] [Related]

  • 53. Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
    Zaware N, Kisliuk R, Bastian A, Ihnat MA, Gangjee A.
    Bioorg Med Chem Lett; 2017 Apr 01; 27(7):1602-1607. PubMed ID: 28258797
    [Abstract] [Full Text] [Related]

  • 54. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
    Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.
    Invest New Drugs; 2011 Dec 01; 29(6):1123-31. PubMed ID: 20467883
    [Abstract] [Full Text] [Related]

  • 55. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D.
    Int J Cancer; 2011 Jul 01; 129(1):245-55. PubMed ID: 21170960
    [Abstract] [Full Text] [Related]

  • 56. Sunitinib.
    Rini BI.
    Expert Opin Pharmacother; 2007 Oct 01; 8(14):2359-69. PubMed ID: 17927489
    [Abstract] [Full Text] [Related]

  • 57. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 58. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 59. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A.
    Oncologist; 2007 Feb 15; 12(2):191-200. PubMed ID: 17296815
    [Abstract] [Full Text] [Related]

  • 60. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Sone S.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.